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The patency of the vascular system is essential to main-
tain normal tissue function. Fortunately for us, the ge-
netic program of vascular cells (endothelial cells, smooth
muscle cells, and fibroblasts) endows them with the ca-
pacity to respond to physiological and pathophysio-
logical stimuli and to rearrange their architecture to
maintain adequate blood flow according to the meta-
bolic demand of the tissue. Rapid calibration of lumen
diameter can occur through vasomotor control governed
by the sympathetic nervous sytem and vasoactive fac-
tors. Long-term structural adaptation, perhaps reflecting
the summation of many short-term vasomotor events,
occurs through a process called “vascular remodeling.”
Vascular remodeling is the ability of the vessel wall
to reorganize its cellular and extracellular components
in response to a chronic stimulus (Gibbons and Dzau
1994). Experimental studies have shown that increases
in blood flow due to an arteriovenous shunt will increase
vessel diameter; conversely, reductions in blood flowwill
reduce vascular diameter. On the basis of these findings,
it is believed that chronic reduction in blood flow ini-
tiates a signaling cascade that leads blood vessels to con-
tract acutely and remodel themselves, creating a smaller
vascular lumen. This remodeling reduces the shear stress
and the circumferential wall strain imposed by the lower
flow rates (Kamiya and Togawa 1980; Langille and
O’Donnell 1986). The layered structure of the vascular
system facilitates information transfer from the lumen
of the vessel into the underlying smooth muscle and then
to surrounding tissue. Likewise, the vessel responds to
neural input and tissue factors to influence the smooth
muscle and the endothelium. The position of the vascular
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endothelium at the interface of blood is ideally situated
to serve as a tranducer, to relay hemodynamic and bi-
ochemical changes into molecular events in the smooth
muscle layer (Davies 1995). Smooth muscle cells in the
medial layer respond to endothelial cell mediators and/
or extracellular matrix (ECM) molecules, allowing ex-
pansion or retraction of smooth muscle mass. The out-
ermost layer, the adventitia, consistsmostly of fibroblasts
and produces growth factors, ECM, and proteases/pro-
tease inhibitors that can regulate proliferation and mi-
gration of smooth muscle cells. Similar remodeling of
the endothelium must also occur during normal angi-
ogenesis, and there is ample evidence showing that in-
creases or decreases in blood flow can influence capillary
densities in the heart and skeletal muscle. This plasticity
of blood vessel architecture is essential for macro- and
microvascular remodeling.
An increasing volume of evidence indicates that ab-
normal vascular remodeling contributes to such cardio-
vascular diseases as hypertension, atherosclerosis, trans-
plant arteriosclerosis, and restenosis. In the past decade,
many molecules essential for vasculogenesis, angioge-
nesis, and vessel structure have been identified that,
when deleted, cause embryonic lethality due to vascular
defects. Although these genes must play fundamental
roles in vascular development or remodeling, we have
little knowledge of the hierarchy of events underlying
physiological or pathological remodeling in the mature
vessel wall. We argue, in the present article, that signals
transmitted bidirectionally across the endotheliumdirect
the remodeling of blood vessel architecture in the adult.
We hypothesize that the inability of the endothelium to
couple hemodynamic events efficiently to the production
of the gaseous second messenger, nitric oxide (NO), con-
tributes to abnormal vascular remodeling in many dis-
eases.
Impaired Vascular Remodeling in Hypertension and
Atherosclerosis
Both human essential hypertension and animalmodels
of this condition show enhanced peripheral vascular re-
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sistance due to impaired remodeling of resistance arte-
rioles. The increase in resistance arises in part because
of impaired structural adaptation to elevated blood pres-
sure and in part because of excess vasoconstriction. In
histologic analysis, this change is measured as an in-
crease in the cross-sectional area of the media, relative
to the area of the lumen of specialized “resistance” ar-
terioles. The increase in media/lumen ratio can result
from any of the following: (1) abnormal lumenal re-
modeling resulting in a narrower lumen, (2) an increase
in muscle mass (wall thickness) with no change in lumen
diameter, or (3) a decrease in external diameter of the
vessel, leading to encroachment of the lumen (Heagerty
et al. 1993). Similarly, in human atherosclerosis there is
ample evidence for active remodeling during the early
stages of disease prior to significant lumenal stenosis.
Compensatory enlargement occurs in peripheral vessels
and in coronary arteries with lesions and represents an
adaptive cellular response to preserve lumen area and
blood flow. This “remodeled” vessel may revert to a
more normal structure if the lesion regresses, but per-
sistent or worsening lesions may provoke an abnormal
remodeling response, thus contributing to occlusive dis-
ease, plaque rupture, and thrombosis (see Birnbaum et
al. 1997 for a comprehensive review).
Although the causes of these diseases are different, in
both cases endothelial dysfunction occurs concomitantly
with changes in vascular structure—that is, with vas-
cular wall thickening in hypertension (Girerd et al. 1994;
Ghiadoni et al. 1998) and with compensatory vessel wall
enlargement in atherosclerosis (Birnbaum et al. 1997).
Endothelial dysfunction, defined here as an impairment
in endothelium-dependent relaxation of blood vessels
(Harrison 1997), is a reversible condition, as evidenced
by the recent clinical trials with drugs such as angioten-
sin-converting enzyme inhibitors (Mancini et al. 1996)
and cholesterol-lowering agents (Treasure et al. 1995).
These functional responses are largely mediated by the
endogenous vasodilator NO, an unusual signaling mol-
ecule that has been identified as the endothelium-derived
relaxing factor—as originally characterized by Furchgott
and Zawadski in 1980.
Mutations in the gene for endothelial isoform of NO
synthase (eNOS) seemed to provide an attractive expla-
nation for these abnormal responses. However, linkage
studies show little evidence that eNOS is a candidate
gene in vascular disease. In patients with essential hy-
pertension (Bonnardeaux et al. 1995; Hunt et al. 1996)
and in genetic models of hypertension in rats (Deng and
Rapp 1997), polymorphisms of the eNOS gene (NOS3)
do not segregate with high blood pressure. This lack of
linkage occurs despite evidence that whole-body basal
NO production in patients with essential hypertension
is diminished (Wang et al. 1997) and that offspring of
hypertensive patients have endothelial dysfunction (Tad-
dei et al. 1996). A recent study in a Japanese population
of patients with essential hypertension has shown that
a missense variant of eNOS (Glu298Asp) is significantly
associated with the disease; however, the functional rel-
evance of this variant is not yet known (Miyamoto et
al. 1998). This same mutation is associated with coro-
nary vasospasm (Yoshimura et al. 1998) and myocardial
infarction (Shimasaki et al. 1998) in this population. A
recent study in France (Lacolley et al. 1998) showed a
higher prevalence of the Glu298 Asp mutation in hy-
pertensives compared with normotensive patients, but
no association between this allele and blood pressure or
aortic stiffness was noted. The only linkage study cor-
relating mutations in the eNOS gene positively with en-
dothelial dysfunction is a study showing a positive as-
sociation between an intronic polymorphism and
patients who were smokers or former smokers with a
history of myocardial infarction (Wang et al. 1996). If
abnormal function or expression of eNOS is involved in
the disease processes associated with endothelial dys-
function, it is unlikely to be a primary determinant of
disease in the populations studied thus far.
The Endothelium as a Sensor for Remodeling
A major breakthrough in understanding the impor-
tance of the endothelium in the remodeling process was
the development of surgical models of flow-dependent
remodeling. Thus, high-flow states, similar to those seen
after long-term exercise training, can be studied by in-
troducing an arterial anastomosis, or flow can be re-
duced in the common carotid artery by ligation of the
external carotid. Using the latter model, which mimics
critical stenosis, Langille andO’Donnell (1986) elegantly
demonstrated that the endothelium, or a substance pro-
duced by the endothelium, was essential for remodeling
toward a smaller lumen after a long-term flow reduction.
Results of this study suggested that the endothelium
sensed the hemodynamic changes and initiated the re-
organization of the preexisting cellular and extracellular
components. This remodeling requires coordinated
changes in cellular proliferation, apoptosis, migration,
cell organization, and matrix-integrin interactions
throughout the layered structure of the vessel. Because
of the complexity of the process, it is not surprising that
it can be perturbed by persistently elevated blood pres-
sures, local inflammation, high cholesterol, or the dep-
osition of oxidized lipids.
NO as a Critical Regulator of Remodeling
Pharmacologic studies using inhibitors of NOS have
implicated NO as an important endothelial mediator of
flow- or pressure- induced arterial remodeling. Long-
term treatment of rats with the NOS inhibitor, nitro-L-
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Figure 1 Allele-dependent abnormal luminal remodeling in
eNOS knockout mice. Wild type (/), heterozygote (/), or ho-
mozygote (/) eNOS knockout mice were exposed to low-flow re-
modeling as described elsewhere (Rudic et al. 1998), and the percent
reduction in lumen diameter of the remodeled left common carotid
artery (relative to the contralateral artery) was measured by quanti-
tative morphometry.
arginine methyl ester (L-NAME), causes a sustained in-
crease in systemic blood pressure accompanied by
marked microvascular remodeling, as judged by an in-
crease in wall-to-lumen ratios of resistance coronary ar-
teries (Numaguchi et al. 1995). Of interest, in this study,
coadministration of hydralazine to offset the pressor ef-
fects of L-NAME did not affect the remodeling of cor-
onary vessels, suggesting that the elevated pressure, per
se, could not account for pathological remodeling. In-
deed, NO is a potent vasodilator, but it may influence
vascular remodeling because of its nonhemodynamic ac-
tions. This signaling molecule has profound effects on
many cell types—inhibiting platelet and leukocyte ad-
herence to the endothelium, promoting endothelial and
preventing smooth muscle–cell migration and prolifer-
ation, influencing extracellular matrix synthesis and deg-
radation, and regulating gene expression. In addition,
NO acts as a second messenger for the actions of many
growth factors, peptides, coagulation factors, and hor-
mones. Luvara et al. (1998) showed that long-term
blockade of whole-body NOS leads to a proinflamma-
tory vascular phenotype associated with the up-regula-
tion of cellular adhesion molecules ICAM-1 andVCAM-
1 and inflammatory cell infiltration. In a study
examining the importance of NO in high-flow remod-
eling of the carotid artery, rabbits with surgically created
arteriovenous fistulas were given nonpressor doses of L-
NAME (Tronc et al. 1996), and remodeling was ex-
amined. As predicted, L-NAME blocked the flow-in-
duced increase in luminal remodeling, supporting the
idea that activation of eNOS by changes in flow pro-
motes NO release and the orchestration of events leading
to remodeling. These results have been corroborated in
rats (Guzman et al. 1997).
Evidence in Genetic Models Implying a Role for NO
in Vascular Remodeling
Recent studies with eNOS knockout mice confirm that
eNOS serves as a major regulator of physiological and
pathological remodeling. eNOS knockout mice are vi-
able, with slightly less than Mendelian segregation of
the appropriate genotypes (Huang et al. 1995; Shesely
et al. 1996; Godecke et al. 1998; Gregg et al. 1998).
The mice are moderately hypertensive, have resting
bradycardia in vivo (Shesely et al. 1996; Godecke et al.
1998), and do not exhibit either pressor responses to L-
NAME or endothelium-dependent relaxations in re-
sponse to acetylcholine (Huang et al. 1995). One of four
studies indicated a trend toward limb-reduction defects
in eNOS knockout mice (Gregg et al. 1998), but all
studies confirm that there were no gross vascular phe-
notypes, showing that eNOS-derived NO is not an es-
sential regulator of vasculogenesis, angiogenesis, or re-
modeling during embryogenesis. Rather, the vascular
roles of NO manifest themselves in the adult mouse.
Rudic et al. (1998) recently developed a mouse model
of physiological remodeling in which ligation of the left
external carotid artery for 2 weeks provokes a reduction
of lumen diameter and medial cell number of the ipsi-
lateral common carotid artery. This reduction in lumen
diameter was triggered by a 30% reduction in blood
flow (R. D. Rudic and W. C. Sessa, unpublished data).
Surprisingly, eNOS mutant mice were unable to reduce
lumen diameter in response to external carotid artery
ligation. Recent data (fig. 1) showed a gene-dosage effect
of disruption of the eNOS locus on impaired luminal
remodeling—that is, loss of one copy of the eNOS gene
yields an intermediate phenotype between control and
homozygote knockout mice. Equally provocative, the
vascular media in abnormally remodeled vessels from
eNOS knockout mice were hyperplastic, as shown by
marked increases in wall thickness, medial nuclei, and
bromodeoxyuridine incorporation. The increase in wall
thickness is reminiscent of the arterial thickening seen
in human hypertension and atherosclerosis. Similar re-
sults were reported by Moroi et al. (1998), using an
injury model initiated by a vascular cuff placed around
the femoral artery of wild type or eNOS knockout mice
(Moroi et al. 1998). This treatment causes marked in-
timal proliferation for both genotypes, but the response
was greatly exaggerated in eNOS knockout mice. Fi-
nally, in studies of ischemic angiogenesis and remodel-
ing, eNOS knockout mice did not revascularize to the
same extent as did wild type mice after hindlimb ische-
mia. Moreover, administration of vascular endothelial
growth factor (VEGF) increased capillary density in wild
type mice, but not in eNOS-deficient mice, supporting
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the idea that VEGF uses NO as a critical second mes-
senger for endothelial cell phenotypes associated with
angiogenesis (Ziche et al. 1994; Papapetropoulos et al.
1997). Collectively, results of these studies indicate that
eNOS is critical to coupling luminal hemodynamics to
a remodeling response, and they imply that NO is likely
the major factor produced by the endothelium required
for physiological remodeling as originally described by
Langille and O’Donnell (1986).
Conclusions and Future Directions
The strong relationship between endothelial dysfunc-
tion and abnormal vascular remodeling is a prominent
feature of many cardiovascular diseases. Endothelium-
derived NO is a powerful regulator of vascular function,
and it appears that abnormalities in the production or
actions of NO lead to endothelial dysfunction and ab-
normal vascular remodeling. The lack of linkage be-
tween eNOS and the disease phenotypes analyzed thus
far argues against a simple model in which eNOS mu-
tations directly cause heritable vascular disease, but it is
possible that further analysis of identified polymor-
phisms may show significant vascular phenotypes.
The critical issues yet to be addressed are the molec-
ular mechanisms by which NO orchestrates the remod-
eling response and the link between cardiovascular dis-
eases and suppressed NO production or bioactivity. Our
ability to engineer mice with desired genotypes should
soon make such questions tractable. For example, breed-
ing eNOS knockout mice to ApoE knockout mice will
allow us to test the importance of NO in vessel adap-
tation and the progression of atherosclerotic lesions.
Similar methods may show genetic and environmental
effects that alter eNOS signaling by influencing ECM
molecules, growth factors, or the fibrinolytic system.
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